ACTIVE LEARNING TEMPLATE: Medication
Montogmery Breda
STUDENT NAME _____________________________________
Ondansetron (Zofran)
MEDICATION __________________________________________________________________________ REVIEW MODULE CHAPTER ___________
5-HT3 antagonists
CATEGORY CLASS ______________________________________________________________________
PURPOSE OF MEDICATION
Expected Pharmacological Action Therapeutic Use
Decreased incidence and severity of nausea and vomiting -Prevention of nausea and vomiting associated w/ highly or
following chemotherapy or surgery by blocking the effects of moderately emetogenic chemotherapy -PO: Prevention of
serotonin at 5-HT3 receptor sites (selective antagonist) nausea and vomiting associated w/ radiation
located in vagal nerve terminals and the chemoreceptor therapy -Prevention and treatment of postoperative nausea
trigger zone in the CNS. and vomiting
Complications Medication Administration
CNS: SEROTONIN SYNDROME, headache, dizziness, drowsiness, PO: Oral tabs disintegrate in
fatigue, weakness CV: TORSADE DE POINTES, QT interval mouth w/out fluid IV Push:
prolongation GI: constipation, diarrhea, abdominal pain, dry mouth,
increase liver enzyems Derm: STEVENS-JOHNSON SYNDROME;
Admin undiluted before
TOXIC EPIDERMAL NECROLYSIS induction of anesthesia or
postoperatively
Contraindications/Precautions
Contraindicated: Hypersensitivity; Orally disintegrating tablets contain
aspartame and should not be used in pats. w/ phenylketonuria;
Congenital long QT syndrome; Concurrent use of apomorphine Nursing Interventions
Caution: Hepatic impairment; Abdominal surgery (may mask ileus);
Assess pat for nausea/vomiting, abdominal
Safety not established in OB: Lactation: or children <3 yr old (PO) or distention/ bowel sounds prior to admin Assess
<1 mon (parenteral) pat for extrapyramidal effect (involuntary
movements, facial grimacing, rigidity, shuffling
walk) Monitor ECG in pat with hyokalemia,
hyomagnesemia, HF, bradyarrhythmias Monitor
for s/s of serotonin syndrom (mental status
Interactions change, autonomic instability, neuromuscular
symptoms, seizures, gastroinestinal symptoms)
Drug-Drug: Use w/ apomorphine increases of severe hypotension and Lab: May cause transient increase in serum
bilirubin, AST, and ALT levels
loss of consciousness/ Carbamazepine, phenytoin, and refampin may
decrease levels; drugs that affect serotonergic neurotransmitters
systems like SSRIs, SNRIs, tricyclic antidepressants, MAOIs,
fentanyl, lithium, buspirone, tramadol, methylene blue, and triptans
increase risk of serotonin syndrome
Client Education
-Take med as directed -Notify
HCP if symptoms of irregular
Evaluation of Medication Effectiveness heart beat, serotonin syndrome,
-Prevent of nausea and vomiting associated with or involuntary movement of
emetogenic cancer chemotherapy -Prevention of eyes, face, or limbs occur
postoperative nausea and vomiting -Prevention of nausea
and vomiting due to radiation therapy
ACTIVE LEARNING TEMPLATES
Montogmery Breda
STUDENT NAME _____________________________________
Ondansetron (Zofran)
MEDICATION __________________________________________________________________________ REVIEW MODULE CHAPTER ___________
5-HT3 antagonists
CATEGORY CLASS ______________________________________________________________________
PURPOSE OF MEDICATION
Expected Pharmacological Action Therapeutic Use
Decreased incidence and severity of nausea and vomiting -Prevention of nausea and vomiting associated w/ highly or
following chemotherapy or surgery by blocking the effects of moderately emetogenic chemotherapy -PO: Prevention of
serotonin at 5-HT3 receptor sites (selective antagonist) nausea and vomiting associated w/ radiation
located in vagal nerve terminals and the chemoreceptor therapy -Prevention and treatment of postoperative nausea
trigger zone in the CNS. and vomiting
Complications Medication Administration
CNS: SEROTONIN SYNDROME, headache, dizziness, drowsiness, PO: Oral tabs disintegrate in
fatigue, weakness CV: TORSADE DE POINTES, QT interval mouth w/out fluid IV Push:
prolongation GI: constipation, diarrhea, abdominal pain, dry mouth,
increase liver enzyems Derm: STEVENS-JOHNSON SYNDROME;
Admin undiluted before
TOXIC EPIDERMAL NECROLYSIS induction of anesthesia or
postoperatively
Contraindications/Precautions
Contraindicated: Hypersensitivity; Orally disintegrating tablets contain
aspartame and should not be used in pats. w/ phenylketonuria;
Congenital long QT syndrome; Concurrent use of apomorphine Nursing Interventions
Caution: Hepatic impairment; Abdominal surgery (may mask ileus);
Assess pat for nausea/vomiting, abdominal
Safety not established in OB: Lactation: or children <3 yr old (PO) or distention/ bowel sounds prior to admin Assess
<1 mon (parenteral) pat for extrapyramidal effect (involuntary
movements, facial grimacing, rigidity, shuffling
walk) Monitor ECG in pat with hyokalemia,
hyomagnesemia, HF, bradyarrhythmias Monitor
for s/s of serotonin syndrom (mental status
Interactions change, autonomic instability, neuromuscular
symptoms, seizures, gastroinestinal symptoms)
Drug-Drug: Use w/ apomorphine increases of severe hypotension and Lab: May cause transient increase in serum
bilirubin, AST, and ALT levels
loss of consciousness/ Carbamazepine, phenytoin, and refampin may
decrease levels; drugs that affect serotonergic neurotransmitters
systems like SSRIs, SNRIs, tricyclic antidepressants, MAOIs,
fentanyl, lithium, buspirone, tramadol, methylene blue, and triptans
increase risk of serotonin syndrome
Client Education
-Take med as directed -Notify
HCP if symptoms of irregular
Evaluation of Medication Effectiveness heart beat, serotonin syndrome,
-Prevent of nausea and vomiting associated with or involuntary movement of
emetogenic cancer chemotherapy -Prevention of eyes, face, or limbs occur
postoperative nausea and vomiting -Prevention of nausea
and vomiting due to radiation therapy
ACTIVE LEARNING TEMPLATES
